Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis through downregulation of ERK and Akt in lung adenocarcinoma A549 cells

Carcinogenesis

Volumn 28, Issue 5, 2007, Pages 1058-1066

  Jin, Cheung Yun ^d   Moon, Dong Oh ^a   Lee, Jae Dong ^d   Heo, Moon Soo ^a   Choi, Yung Hyun ^b   Lee, Chang Min ^c   Park, Yeong Min ^c   Kim, Gi Young ^a  

^a Jeju National University   (South Korea)

^b Dong Eui University   (South Korea)

^c Pusan National University School of Medicine   (South Korea)

^d Pusan National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; DEATH RECEPTOR 5; DNA FRAGMENT; LACTATE DEHYDROGENASE; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; SULFORAPHANE; ANTINEOPLASTIC AGENT; SULFORAFAN; THIOCYANIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL VIABILITY; CHROMATIN CONDENSATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DNA CONTENT; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME RELEASE; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; PRIORITY JOURNAL; SENSITIZATION; ADENOCARCINOMA; LUNG TUMOR; METABOLISM; TUMOR CELL LINE;

ADENOCARCINOMA; ANTICARCINOGENIC AGENTS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; DOWN-REGULATION; HUMANS; LUNG NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; THIOCYANATES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34447097884     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl251     Document Type: Article

References (39)

1. Kischkel, F.C. et al.. (2000) Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12, 611-620.
2. Van Geelen, C.M. et al.. (2004) Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: Paving the road to patient-tailored therapy. Drug Resist. Updat., 7, 345-358.
3. Srivastava, R.K. (2001) TRAIL/Apo-2L: Mechanisms and clinical applications in cancer. Neoplasia, 3, 535-546.
4. Shankar, S. et al.. (2004) Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: Mechanisms and clinical implications. Drug Resist. Updat., 7, 139-156.
5. LeBlanc, H. et al.. (2002) Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat. Med., 8, 274-281.
6. Kim, E.H. et al.. (2004) Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene, 23, 446-456.
7. Fahey, J.W. et al.. (2002) Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo [a]pyrene-induced stomach tumors. Proc. Natl Acad. Sci. USA, 99, 7610-7615.
8. Singh, S.V. et al.. (2005) Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species. J. Biol. Chem., 20, 19911-19924.
9. Chi-Tai, Y. et al. (2005) Effect of sulforaphane on metallothionein expression and induction of apoptosis in human hepatoma HepG2 cells. Carcinogenesis, 26, 2138-2148.
10. Jackson, SJ, et al.. (2004) Sulforaphane: A naturally occurring mammary carcinoma mitotic inhibitor, which disrupts tubulin polymerization. Carcinogenesis, 25, 219-227.
11. Myzak, M.C. et al.. (2006) Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCap and PC-3 prostate epithelial cells. Carcinogenesis, 27, 811-819.
12. Kim, H. et al. (2006) Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5. Cancer Res., 1, 1740-1750.
13. Hu, L. et al.. (2002) Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res., 62, 1087-1092.
14. Asselin, E. et al.. (2001) XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res., 61, 1862-1868.
15. Wang, Q. et al.. (2002) Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3′-kinase inhibition in the KM20 human colon cancer cell line. Clin. Cancer Res., 8, 1940-1947.
16. Chen, X. et al. (2001) Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene, 20 6073-6083.
17. Martellin, A.M. et al.. (2003) A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia, 17, 1794-1805.
18. Thakkar, H. et al.. (2001) Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance. J. Biol. Chem., 276, 38361-38369.
19. Sah, N.K. et al.. (2003) Translation inhibitors sensitize prostate cancer cells to apoptosis induced by tumor necrosis factor-related apoptosis inducing ligand (TRAIL) by activating c-Jun N-terminal kinase. J. Biol. Chem., 278, 20593-20602.
20. Jakubikova, J. et al.. (2005) Role of PI3K/Akt and MEK/ERK signaling pathways in sulforaphane- and erucin-induced phase II enzymes and MRP2 transcription, G2/M arrest and cell death in Caco-2 cells. Biochem. Pharmacol., 1, 1543-1552.
21. Xu, C. et al.. (2006) ERK and JNK signaling pathways are involved in the regulation of activator protein 1 and cell death elicited by three isothiocyanates in human prostate cancer PC-3 cells. Carcinogenesis, 27, 437-445.
22. Roy, N. et al. (1997) The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J., 16, 6914-6925.
23. Thatcher, N. (2001) Chemotherapy for advanced non-small cell lung cancer. Lung Cancer, 34, 171-175.
24. Krzakowski, M. (2001) New agents within the preoperative chemotherapy of non-small cell lung cancer. Lung Cancer, 34, 159-163.
25. Srivastava, R.K. (2000) Intracellular mechanisms of TRAIL and its role in cancer therapy. Mol. Cell. Biol. Res. Commun., 4, 67-75.
26. Walczak, H. et al. (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med., 5 157-163.
27. French, L.E. et al. (1999) The TRAIL to selective tumor death. Nat. Med., 5, 146-147.
28. Muzio, M. (1998) Signalling by proteolysis: Death receptors induce apoptosis. Int. J. Clin. Lab. Res., 28, 141-147.
29. Green, D.R. et al. (1998) Mitochondria and apoptosis. Science 281, 1309-1312.
30. Kandasamy, K. et al. (2002) Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res., 62, 4929-4937.
31. Kim, Y.H. et al. (2004) Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis, 25, 1813-1820.
32. Jung, E.M. et al. (2005) Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5). Carcinogenesis, 26, 1905-1913.
33. Matsui, T.A. et al. (2006) Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells. Carcinogenesis, in press.
34. Cohen, G.M. (1997) Caspases: The executioners of apoptosis. J. Biochem., 326, 1-16.
35. Stennicke, H.R. et al. (1998) Properties of the caspases. Biochim. Biophys. Acta, 1387, 17-31.
36. Earnshaw, W.C. et al. (1999) Mammalian caspases: Structure, activation, substrates, and functions during apoptosis. Annu. Rev. Biochem., 68, 383-424.
37. Xia, Z. et al. (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science, 270, 1326-1331.
38. Kennedy, S.G. et al. (1997) The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev., 11, 701-713.
39. Park, S.Y. et al. (2002) Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis. Biochem. Biophys. Res. Commun., 12, 515-518.